Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 12, Pages 2168-2172Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw424
Keywords
antibody drug conjugate; ADC
Categories
Ask authors/readers for more resources
Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available